Augment Investments has announced its acquirement of an additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the completion of the transaction.
Augment Investments has announced to acquire additional 10.032% stake in Pharmstandard OJSC, from Bristley Enterprises, to become a 79.8% stake holder in the company, upon the completion of the transaction.
According to the transaction, Augment will hold 15.2m global depository receipts (GDS) of Pharmstandard.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Recognised with 2025 Excellence Awards for Research and Development and Marketing, Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.
